Labetalol Stragen

Labetalol, the active ingredient in Labetalol Stragen, is a alpha/beta adrenergic blocker presented as an intravenous formulation for intravenous use. It treats hypertension and hypertensive emergencies in adult patients. GNH USA supplies Labetalol Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Labetalol is used to manage conditions related to elevated blood pressure and vascular resistance.

Hypertension: lowers systemic blood pressure by reducing cardiac output and peripheral vascular resistance. Hypertensive emergencies: provides rapid blood pressure control in acute, life‑threatening situations. Acute severe hypertension: stabilises patients with sudden, marked elevations in arterial pressure.

Common Side Effects: - Dizziness or light‑headedness - Headache - Nausea or vomiting - Fatigue or weakness - Flushing or warmth sensation - Tachycardia or palpitations

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Bronchospasm, especially in patients with asthma - Hepatic dysfunction or elevated liver enzymes - Heart block or severe bradyarrhythmias - Anaphylactic or severe allergic reactions - Acute heart failure or pulmonary edema

Labetalol should be used with clinical monitoring and awareness of specific safety considerations. - Blood pressure monitoring: check frequently during initiation and dose adjustments. - Asthma or chronic obstructive pulmonary disease: use cautiously due to potential bronchospasm. - Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension. - Hepatic impairment: consider dose reduction and monitor liver function. - Diabetes: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms. - Store at room temperature: keep in original container, protect from moisture and light.

Labetalol may interact with several drug classes that affect cardiovascular function.

Major Interactions (Avoid): - Other antihypertensives (e.g., additional β‑blockers, ACE inhibitors) – risk of excessive hypotension. - Calcium channel blockers such as verapamil – additive negative inotropic effect. - Monoamine oxidase inhibitors – potential for severe hypertension. - Clonidine – abrupt withdrawal may cause rebound hypertension. - Epinephrine or other sympathomimetics – antagonistic effect reducing therapeutic response.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs – may blunt antihypertensive effect. - Diuretics – monitor electrolytes and blood pressure. - Antidepressants (SSRIs, SNRIs) – possible additive central nervous system effects. - Anesthetic agents – may enhance cardiovascular depression. - Antiarrhythmic drugs – monitor cardiac rhythm for bradyarrhythmias.